Current status of nanoscale drug delivery systems for colorectal cancer liver metastasis - 17/05/19

Doi : 10.1016/j.biopha.2019.108764

Yun Hong, Yuefeng Rao ^⁎
The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang Province, 310003, China

^⁎Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

pages	10
Iconographies	1
Vidéos	0
Autres	0

Abstract

Tumor metastasis is a major cause of colorectal cancer-related deaths. The liver is a common site of colorectal cancer metastasis. There is no effective treatment for patients with colorectal cancer with liver metastasis. Due to the complicated and variable metastasis process, the current treatment methods for colorectal cancer liver metastasis cannot meet the clinical needs. Currently, no effective delivery system is available for clinical use which could specifically target metastatic cancers. The emergence of nanoscale drug delivery systems indicates a new direction for the treatment of colorectal cancer liver metastasis. This article summarizes the current common drug and metastasis-related signaling pathways for the treatment of hepatic metastatic colorectal cancer. This review introduces the progress of use nano-formulations for liver metastatic colorectal cancer and provides new ideas.

Le texte complet de cet article est disponible en PDF.

Keywords : Colorectal cancer liver metastasis, Pathological process, Correlated signaling pathway, Nanoscale drug delivery system, Imaging diagnosis